A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular Carcinoma

April 1, 2020 updated by: Hoffmann-La Roche

A Randomised, Placebo-controlled, Double-blind, Multicenter Phase II Trial of Intravenous GC33 at 1600 mg Q2W in Previously Treated Patients With Unresectable Advanced or Metastatic Hepatocellular Carcinoma (HCC)

This randomized, placebo-controlled, multicenter study will evaluate the efficacy and safety of GC33 (RO5137382) in previously treated patients with unresectable advanced or metastatic hepatocellular carcinoma. Participants will be stratified according to the level of GPC-3 expression in tumors and randomized to receive either GC33 (1600 mg intravenously) or placebo on Days 1 and 8 of Cycle 1 and every 2 weeks thereafter. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

185

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Belgium
      • Bruxelles, Belgium, 1070
        • Hospital Erasme
      • Gent, Belgium, 9000
        • UZ Gent
  • France
      • Angers, France, 49033
        • Hotel Dieu; Medecine A
      • Grenoble, France, 38 043
        • CHU de GRENOBLE; UF de Cancérologie
      • Marseille, France, 13385
        • Aphm; Hopital De La Conception
      • Nice, France, 06202
        • Hopital de L'Archet; Pole de Reference Hepatite C
      • Paris, France, 75571
        • Hôpital Saint Antoine; Service Hépathologie
      • Toulouse, France, 31059
        • Hopital Purpan;Gastro Enterologie Hepatologie
      • Vandoeuvre-les-nancy, France, 54511
        • Hôpital d'Adultes; Service hépato-gastro-entérologie
  • Germany
      • Berlin, Germany, 13353
        • Charité Uni.-medizin Berlin, Campus Virchow-Klinikum; Med. Klinik m.S. Hepatologie Gastroenterologie
      • Frankfurt Am Main, Germany, 60590
        • Klinik Johann Wolfgang von Goethe Uni; Zentrum der Inneren Medizin; Medizinische Klinik I
      • Heidelberg, Germany, 69120
        • Uni Heidelberg Med. Klinik; Innere Medizin IV
      • Leipzig, Germany, 04103
        • Universitätsklinikum Leipzig
      • Muenchen, Germany, 81675
        • Klinikum rechts der Isar der TU München; Klinikapotheke
  • Hong Kong
      • Pokfulam, Hong Kong
        • Queen Mary Hospital; Dept of Surgery
      • Shatin, Hong Kong
        • Prince of Wales Hosp; Dept. Of Clinical Onc
  • Italy
    • Campania
      • Benevento, Campania, Italy, 82100
        • Azienda Ospedaliera G. Rummo; Unità Operativa di Oncologia Medica 1
    • Lazio
      • Roma, Lazio, Italy, 00168
        • Policlinico Universitario Agostino Gemelli
    • Lombardia
      • Milano, Lombardia, Italy, 20122
        • Fondazione IRCCS Ospedale Maggiore Policlinico; Gastroenterologia
  • Japan
      • Chiba, Japan, 277-8577
        • National Cancer Center Hospital East
      • Ishikawa, Japan, 920-8641
        • Kanazawa University Hospital
      • Kanagawa, Japan, 241-8515
        • Kanagawa Cancer Center
      • Osaka, Japan, 589-8511
        • Kindai University Hospital
      • Tokyo, Japan, 104-0045
        • National Cancer Center Hospital
      • Tokyo, Japan, 181-8611
        • Kyorin University Hospital
  • Korea, Republic of
      • Busan, Korea, Republic of, 602-739
        • Pusan University Hospital
      • Gyeonggi-do, Korea, Republic of, 10408
        • National Cancer Center
      • Seoul, Korea, Republic of, 03722
        • Severance Hospital, Yonsei University Health System
      • Seoul, Korea, Republic of, 05505
        • Asan Medical Center
      • Seoul, Korea, Republic of, 06351
        • Samsung Medical Center
      • Seoul, Korea, Republic of, 06591
        • Seoul St Mary's Hospital
  • New Zealand
      • Auckland, New Zealand, 100
        • Auckland Hospital; New Zealand Liver Transplant Unit
  • Singapore
      • Singapore, Singapore, 169610
        • National Cancer Centre; Medical Oncology
  • Spain
      • Barcelona, Spain, 08035
        • Hospital Universitari Vall d'Hebron; Servicio de Hepatologia
      • Barcelona, Spain, 08036
        • Hospital Clínic i Provincial; Servicio de Hematología y Oncología
      • Madrid, Spain, 28041
        • Hospital Universitario 12 de Octubre; Servicio de Oncologia
      • Madrid, Spain, 28040
        • Hospital Universitario Clínico San Carlos; Servicio de Oncologia
      • Madrid, Spain, 28007
        • Hospital General Universitario Gregorio Marañon; Servicio de Oncologia
      • Madrid, Spain, 28007
        • Hospital General Universitario Gregorio Marañon
      • Zaragoza, Spain, 50009
        • Hospital Universitario Miguel Servet; Servicio Hematologia
    • Cantabria
      • Santander, Cantabria, Spain, 39008
        • Hospital Universitario Marques de Valdecilla; Servicio de Oncologia
  • Taiwan
      • Kaohsiung, Taiwan, 00833
        • Chang Gung Memorial Foundation - Kaohsiung
      • Taichung, Taiwan, 40705
        • Taichung Veterans Gen Hosp
      • Tainan, Taiwan, 00704
        • National Cheng Kung Univ Hosp
      • Taipei, Taiwan, 100
        • National Taiwan Uni Hospital; Dept of Oncology
      • Taipei City, Taiwan, 112
        • Taipei Veterans General Hospital
  • United Kingdom
      • Bebington, United Kingdom, CH63 4JY
        • The Clatterbridge Cancer Ctr NHS Foundation Trust
      • London, United Kingdom, NW3 2QG
        • Royal Free Hospital; Dept of Oncology
      • London, United Kingdom, SE5 9RS
        • King'S College Hospital; Haematology
  • United States
    • California
      • Los Angeles, California, United States, 90095
        • UCLA Medical Center
    • Maryland
      • Bethesda, Maryland, United States, 20889-0001
        • National Cancer Institute; Ctr for Cancer Research
    • Michigan
      • Detroit, Michigan, United States, 48201
        • Barbara Ann Karmanos Cancer Institute
    • Missouri
      • Saint Louis, Missouri, United States, 63110
        • Washington Univ School of Med; Barnes-Jewish Hospital; Siteman Cancer Center
    • New York
      • New York, New York, United States, 10032
        • Columbia University Medical Center
      • New York, New York, United States, 10065
        • Memorial Sloan Kettering Cancer Center
    • Tennessee
      • Nashville, Tennessee, United States, 37232-7610
        • Vanderbilt Medical Center
    • Washington
      • Seattle, Washington, United States, 98104
        • Swedish Cancer Inst.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Adult patients, >/= 18 years of age
  • Histologically confirmed hepatocellular carcinoma (without fibro-lamellar subtype)
  • Prior treatment with at least 1 systemic agent, with documented progressive disease after systemic agent(s), or documented adverse event(s) associated with prior systemic agent(s) that resulted in discontinuance of that (those) agent(s)
  • Not a candidate for curative treatments (e.g. resection, transplantation)
  • Child-Pugh A (score of 5-6)
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • Adequate hematologic, hepatic and renal function
  • Ability to provide, for central review, a tumor tissue sample to determine the level of GPC-3 expression by IHC
  • Measurable disease by RECIST criteria

Exclusion Criteria:

  • Child Pugh B or C
  • Known hepatocellular carcinoma with fibro-lamellar histology
  • Known brain or leptomeningeal metastases
  • Active infectious diseases requiring treatment except for hepatitis B and C
  • History of organ allograft including liver transplant
  • Anticipated or ongoing administration of anticancer therapies other than those administered in this study
  • Anticancer treatment within 2 weeks prior to entering the study
  • Patients who have not fully recovered from toxicities associated with previous HCC loco-regional or systemic therapies
  • Patients receiving interferon therapy
  • Pregnant or lactating women
  • Known HIV positivity or AIDS-related illness
  • History of significant hypersensitivity to similar agents (monoclonal antibody, protein-included drugs, Chinese hamster ovary products)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo
Drug: Placebo
iv Days 1 and 8, and every 2 weeks thereafter
Experimental: GC33 (RO5137382)
Drug: GC33
1600 mg iv Day 1 and 8, and every 2 weeks thereafter
Other Names:
  • RO5137382

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Progression-free survival (tumor assessments according to RECIST criteria)
Time Frame: approximately 24 months
approximately 24 months

Secondary Outcome Measures

Outcome Measure
Time Frame
Safety: Incidence of adverse events
Time Frame: approximately 24 months
approximately 24 months
Overall survival
Time Frame: approximately 32 months
approximately 32 months
Time to progression (TTP): Time from randomization to first documented disease progression
Time Frame: approximately 24 months
approximately 24 months
Disease control rate (DCR): Complete response, partial response or stable disease lasting at least 6 weeks
Time Frame: approximately 24 months
approximately 24 months
Pharmacokinetics: Serum concentrations (Cmax,Cmin)
Time Frame: Multiple sampling pre- and post-dose Days 1 and 8 Cycle 1, Day 1 Cycle 6, pre-dose Day 1 Cycles 2-11
Multiple sampling pre- and post-dose Days 1 and 8 Cycle 1, Day 1 Cycle 6, pre-dose Day 1 Cycles 2-11
GPC-3 expression in tumor tissue (biopsy) by immunohistochemistry (IHC) assay
Time Frame: at screening
at screening

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hoffmann-La Roche

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 2, 2012

Primary Completion (Actual)

August 20, 2015

Study Completion (Actual)

August 20, 2015

Study Registration Dates

First Submitted

January 6, 2012

First Submitted That Met QC Criteria

January 6, 2012

First Posted (Estimate)

January 10, 2012

Study Record Updates

Last Update Posted (Actual)

April 3, 2020

Last Update Submitted That Met QC Criteria

April 1, 2020

Last Verified

April 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NP27884
  • 2011-003574-84 (EudraCT Number)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Carcinoma, Hepatocellular

Clinical Trials on Placebo

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Greece

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe